Abstract:Different crystal forms of pharmaceutically important compounds demonstrate non-equivalent physical properties and, thus, bioactivity. Taking into consideration the polymorphism is crucial for many applications due to the prominent variation in properties of solids of the same chemical substance but with different crystal packing. The structure of 4-oxo-4-phenylbutanoic acid, C 10 H 10 O 3 , at 120 K has monoclinic ( P 2 1 /c ) symmetry and is a Z = 8, Z ′ = 2 polymorph (γ-form). The previously published two polymorphs with CCDC codes VERMAG (α-form) and VERMAG01 (β-form) crystallize with Z = 4, Z ′ = 1 in the monoclinic space groups P 2 1 /c [ a = 15.071 (10), b = 5.435 (9), c = 16.058 (10), β = 129.57 (10)°] and P 2 1 /n [ a = 12.728 (6), b = 5.200 (3), c = 14.426 (6), β = 111.33 (3)°], respectively. Reported herein polymorph has a significantly larger cell volume of 1754.51 Å 3 [ a = 15.2673 (6), b = 5.2028 (2), c = 22.3063 (8), β = 98.0217 (7)°]. Structurally, the γ-form differs from the two other known (RMSD does not exceed 0.2 Å). Only reported herein polymorph contains weak attractive C7—H7A···O3A close contacts between two neighboring molecules, giving some structural variety of the two crystallographically independent molecules as well as slight non-coplanarity between their phenyl rings. The previously reported polymorphs demonstrate carbonyl groups at position 4 unaffected. All polymorphs contain dimers of molecules bounded by two equivalent intermolecular hydrogen bonds. Investigation of three polymorphs of 4-oxo-4-phenylbutanoic acid highlights the importance of understanding the relationship between various parameters such as packing density, presence of different interactions within the crystal, and energy of the crystal lattice. This is of great importance for the development of new materials with specific physical properties and applications in various fields of science and technology, such as dyes and pigments, high-energy materials, and pharmaceuticals.

Form IV of carbamazepine.

Comparison of the Four Anhydrous Polymorphs of Carbamazepine and the Crystal Structure of Form I.

Crystal Structure and Twisted Aggregates of Oxcarbazepine Form III

Crystal Structure of Ethyl 1-(4-fluorobenzyl)-3-phenyl-1h-pyrazole-5-carboxylate, C19H17FN2O2

The Polymorphic Drug Substances of the European Pharmacopoeia. Part 9. Physicochemical Properties and Crystal Structure of Acetazolamide Crystal Forms

Thermodynamic Investigation of Carbamazepine-Saccharin Co-Crystal Polymorphs

Template-directed crystallization of carbamazepine form II from palmitic acid melt – a key to understand mechanically-induced polymorphism of carbamazepine

From Crystalline to Amorphous Structure of Carbamazepine Regulated by Dipeptide-Based Supramolecular Gel

Crystal Structures and Thermodynamic Properties of New Atypical Antipsychotic Cariprazine and Its Hydrochloride

Crystal Structure of Metformin Ethyl N-(3-tossulfonyl)carbamate

Virtual Screening, Structural Analysis, and Formation Thermodynamics of Carbamazepine Cocrystals

Formation Thermodynamics of Carbamazepine with Benzamide, Para-Hydroxybenzamide and Isonicotinamide Cocrystals: Experimental and Theoretical Study

The crystal structure of N,N′-carbonylbis(2,6-difluorobenzamide), C 15 H 8 F 4 N 2 O 3

Spray Drying as a Reliable Route to Produce Metastable Carbamazepine Form IV

Crystal Form and Transformation of Clarithromycin

Crystal structure of cariprazine dihydrochloride, C 21 H 34 Cl 2 N 4 OCl 2

Crystal structure, packing features, DFT evaluation of intermolecular hydrogen bonds, and crystal lattice energy of a polymorph of 4-oxo-4-phenylbutanoic acid

Cocrystals of carbamazepine: Structure, mechanical properties, fluorescence properties, solubility and dissolution rate

A New Polymorphic Form of Metoprolol Succinate

Exploring Carbamazepine Polymorph Crystal Growth in Water by Enhanced Sampling Simulations

Proposed crystal structure of carbadox, C 11 H 10 N 4 O 4